FDA has completed a preliminary review of such reports for 8 antidepressant drugs (citalopram, fluoxetine, fluvoxamine, mirtazapine, nefazodone,
paroxetine, sertraline,
and venlafaxine) studied under the pediatric exclusivity provision,
and has determined that additional data and analysis, and also a public discussion of available data, are needed.